Compare Moderna, Inc. (MRNA) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Tripadvisor Inc Common Stock — how do they compare? Moderna, Inc. trades at $135.84 (market cap $56.02B), while Tripadvisor Inc Common Stock trades at $8.79 (market cap $1.07B). The key difference: Moderna, Inc. is far larger — about 52.4× Tripadvisor Inc Common Stock's market cap, and Moderna, Inc. is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| MRNA | TRIP | |
|---|---|---|
Market Cap | $56.02B | $1.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $174.38 | $19.14 |
52-Week Low | $22.36 | $8.82 |
Enterprise Value | $52.17B | $1.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Tripadvisor (TRIP) trades at $9.085, down 2.57% for the day, reflecting ongoing pressure from recent earnings misses and competitive challenges. The stock shows bearish technical signals with mixed oscillators, while fundamentals reveal strong gross margins (92.11%) but thin net income (0.27%). Recent news highlights insider selling and TheFork subsidiary sale, creating uncertainty about growth prospects amid AI-driven travel competition.
The outlook remains cautious with analyst consensus leaning Hold (62.5%) despite a $11.80 price target suggesting 30% upside. Key risks include persistent earnings volatility, market share erosion to AI platforms, and declining cash flow trends. Investment opportunity hinges on Viator's performance and successful execution of strategic initiatives post-TheFork divestiture.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
